Poor
Mostly Not Aligned
Patient Risk:
Moderate
Summary
Only a subset of statements are label-supported (indications and mechanism at a high level). Most claims are outside the provided FDA label excerpts (pricing, availability, patents, pharmacy stocking, bioequivalence language, and purchase/brand-manufacturing statements) and therefore cannot be verified from the supplied prescribing information; several are potentially inconsistent with what can be concluded from the excerpted label.
Category Scores
Accurate Statements
Amlodipine is used to treat high blood pressure.
Label Section 1.1 Hypertension: NORVASC is indicated for the treatment of hypertension, to lower blood pressure.
Amlodipine is used to treat angina.
Label Section 1.2 CAD: indications include chronic stable angina and vasospastic angina.
Amlodipine works by relaxing blood vessels.
Label Section 12.1/12.1 (vascular effects): amlodipine is a peripheral arterial vasodilator to reduce peripheral vascular resistance and blood pressure.
Relaxing blood vessels helps lower blood pressure with amlodipine.
Label Section 12.1 (vascular effects): reduction in peripheral vascular resistance and reduction in blood pressure.
Relaxing blood vessels improves blood flow to the heart with amlodipine.
Supported at most indirectly by reduction in blood pressure/peripheral resistance and the angina indication; however the excerpt does not explicitly state 'improves blood flow to the heart.'
Unsupported Statements
Norvasc is the brand name for amlodipine.
Not supported in the provided excerpts; the label excerpt uses NORVASC/amlodipine but does not explicitly state 'Norvasc is the brand name for amlodipine' in a directly matchable sentence.
A typical 10 mg tablet of Norvasc might range from approximately PHP 25 to PHP 50 in the Philippines.
Pricing and geography are not addressed in the provided FDA label excerpts.
A box of 30 tablets of Norvasc might cost around PHP 750 to PHP 1500 in the Philippines.
Pricing and geography are not addressed in the provided FDA label excerpts.
Generic versions of amlodipine are widely available in the Philippines.
Availability by country/pharmacy is not addressed in the provided FDA label excerpts.
Generic amlodipine is considerably less expensive than Norvasc.
Cost comparison is not addressed in the provided FDA label excerpts.
Generic versions of amlodipine offer the same active ingredient and therapeutic effect as Norvasc.
The provided excerpts do not discuss generics, therapeutic equivalence, or substitution.
Generic amlodipine is sold under different brand names or simply as "amlodipine".
The provided excerpts do not discuss generic naming or marketing.
A box of 30 generic 10 mg amlodipine tablets might cost between PHP 150 and PHP 300 in the Philippines.
Pricing and geography are not addressed in the provided FDA label excerpts.
The original patents for amlodipine have long expired.
Patent status is not addressed in the provided FDA label excerpts.
Patent expiry has allowed widespread availability of generic versions globally, including in the Philippines.
Global availability/patent causality is not addressed in the provided FDA label excerpts.
Norvasc and generic alternatives can be purchased at most licensed pharmacies throughout the Philippines.
Pharmacy stocking/purchasing logistics are not addressed in the provided FDA label excerpts.
Major pharmacy chains such as Watsons, Mercury Drug, and Generika Drugstore typically stock Norvasc or generic amlodipine.
Specific retailers/stocking are not addressed in the provided FDA label excerpts.
A prescription from a qualified healthcare professional is generally required to purchase amlodipine.
Prescription requirements are not addressed in the provided FDA label excerpts.
Norvasc is the original brand-name medication manufactured by Pfizer.
Manufacturer/corporate entity is not addressed in the provided FDA label excerpts.
Generic amlodipine is produced by various pharmaceutical companies after expiration of Norvasc's patents.
Generic production and patent-exiration timing are not addressed in the provided FDA label excerpts.
Both Norvasc and generic amlodipine contain the same active ingredient, amlodipine.
While NORVASC contains amlodipine (as presented), the excerpts do not address generics or claims about generic products.
Norvasc and generic amlodipine are bioequivalent, meaning they work the same way in the body.
The provided excerpts do not discuss bioequivalence or equivalence of generics.
Amlodipine is prescribed to prevent chest pain (angina).
The label excerpts indicate symptomatic treatment of chronic stable angina and treatment of vasospastic angina; they do not explicitly use 'prevent' language.
Relaxing blood vessels improves blood flow to the heart with amlodipine.
The provided excerpts do not explicitly state improved cardiac blood flow; they describe vascular effects and indications.
Contradictions
Low
AI Statement
Amlodipine is prescribed to prevent chest pain (angina).
Label Reference
Label Section 1.2 CAD describes 'symptomatic treatment' of chronic stable angina and 'treatment' of vasospastic angina, not prevention.
Important Omissions
None of the label-required prescribing details (e.g., NORVASC starting dose and maximum dose; contraindication wording; warnings such as hypotension or worsening angina/MI; specific drug interaction monitoring requirements) are included in the AI response, which focuses on non-label topics (pricing/availability).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response largely omits label safety-critical information and includes several unsupported generalizations about interchangeability and procurement; while it does not directly claim specific harmful dosing, unsupported equivalence/availability statements could mislead readers.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Not Aligned
Primary Issue
Many claims are not supported by the provided FDA label excerpts (pricing, patents, availability/pharmacy stock, manufacturer/patent history, generic substitution/bioequivalence, and procurement/prescription requirements). Several clinical wording claims are also not aligned precisely with labeled indications (e.g., 'prevent' vs 'treat/symptomatic treatment').
Suggested Improvement
Limit statements to label-supported items: labeled indications (hypertension; chronic stable angina; vasospastic angina; angiographically documented CAD reduction in hospitalization/revascularization risk), labeled dosing ranges (initial 5 mg daily; max 10 mg daily; 2.5 mg for certain patients), the listed contraindication (known sensitivity to amlodipine), and labeled warnings/precautions (e.g., symptomatic hypotension; increased angina/MI after start/increase; titrate slowly in severe hepatic impairment). Remove or qualify all non-label claims about prices, patents, pharmacy availability, manufacturer identity, and generic bioequivalence.